论文部分内容阅读
目的：探讨P16蛋白与肾盂癌病理分级、临床分期、预后及肿瘤增生活性的关系。方法：采用免疫组织化学技术对31例肾盂癌标本中P16蛋白表达进行检测。结果：31例肾孟癌P16蛋白表达阳性率为581％，其中Ⅰ级、Ⅱ级和Ⅲ级肿瘤阳性率分别为75．0％、66.7％和25．0％（P＜0．05），T1～T2和T3～T4期肿瘤阳性率分别为66.7％和462％（P＜0．05）。显示P16蛋白表达阳性率随肾孟癌病理分级、临床分期的上升而降低。P16蛋白表达阳性者3年生存率与表达防性者及肿瘤增生活性均有显著性差异。结论：P16蛋白对阻止肾盂癌恶性发展起重要作用，其检测可用于评估肾盂癌的恶性度及预后。
Objective: To investigate the relationship between P16 protein and pathological grade, clinical stage, prognosis and tumor proliferative activity of renal pelvic cancer. Methods: Immunohistochemical technique was used to detect the expression of P16 protein in 31 cases of renal pelvic cancer. Results: The positive rate of P16 protein expression was 581% in 31 cases of renal cell carcinoma, and the positive rates of grade Ⅰ, Ⅱ and Ⅲ tumors were 75.0%, 66.7% and 25.0% respectively (P <0.05) The positive rates of T1 ~ T2 and T3 ~ T4 tumors were 66.7% and 462% respectively (P <0.05). The positive rate of P16 protein expression with the pathological grading of renal cell carcinoma, clinical stage and decreased. P16 protein expression positive 3-year survival rate and expression of anti-tumor and tumor proliferation were significantly different. Conclusion: P16 protein plays an important role in preventing the malignant development of renal pelvic cancer. The detection of P16 protein can be used to evaluate the malignancy and prognosis of renal pelvic cancer.